flâneur

Reverse Voxsplaining: Brand-Name Drugs | Slate Star Codex

slatestarcodex.com · 59,431 words · saved by 1 readers

Earlier this week I wrote about how a lack of drug price regulation in the United States allows pharmaceutical companies — including EpiPen’s manufacturer, Mylan — to charge exceptionally high prices for their products. Scott Alexander at the blog Slate Star Codex argues that I’ve got it all wrong: The problem isn’t a lack of price regulation. Instead, its too much regulation, which has prevented generic competitors from entering the market and has left EpiPen’s price so high. […] Alexander and I are both essentially pointing out two examples of how the United States has created a regulatory system that is incredibly favorable to pharmaceutical companies. We’ve set up a system that makes it incredibly easy for drug companies to score high profits and charge exceptionally high prices for their products. One way it’s favorable is that we let drug companies pick their own prices — in this way the United States is exceptional, as the vast majority of developed companies regulate their drug

Reverse Voxsplaining: Brand-Name Drugs | Slate Star Codex Home About / Top Posts Archives Top Posts Comments Feed RSS Feed Slate Star Codex Blogroll Economics Artir Kel Bryan Caplan David Friedman Pseudoerasmus Scott Sumner Tyler Cowen Effective Altruism 80000 Hours Blog Effective Altruism Forum GiveWell Blog Rationality Alyssa Vance Beeminder Elizabeth Van Nostrand Gwern Branwen Jacob Falkovich Jeff Kaufman Katja Grace Kelsey Piper Less Wrong Paul Christiano Robin Hanson Sarah Constantin Zack Davis Zvi Mowshowitz Science Andrew Gelman Greg Cochran Michael Caton Razib Khan Scott Aaronson Steph

related reading